FDA Approves Talazoparib for Metastatic Prostate Cancer

The oral PARP inhibitor talazoparib in combination with enzalutamide provides a new treatment option for patients with HRR gene–mutated metastatic castration-resistant prostate cancer.
Medscape Medical News Read More